Veeda Clinical Research IPO

Founded in April 2004, Veeda Clinical Research Limited is a full-service contract research organization (CRO) providing a comprehensive range of services in drug development, including non-clinical, pre-clinical, bioavailability, bioequivalence studies, and clinical trials for various drugs such as novel entities, generics, and biosimilars, as well as medical devices. The company's services include the following. Early-phase and late phase clinical trials Healthy volunteer studies (“HVS”) which include bioavailability studies and bioequivalence studies Pre-clinical trials and non-clinical testing biopharma services include non-clinical analysis and clinical bioanalysis of large molecules. As of September 30, 2024, the company completed 119 global regulatory inspections in HVS and Pre-Clinical services by authorities including the FDA, UK-MHRA, WHO, ANVISA, DCGI, EMA, and NPRA. As of September 30, 2024, the company has over 436 active clients worldwide. The company has successfully conducted studies for 417, 504, 498, and 580 clients during the six months ending September 30, 2024, and for the financial years 2024, 2023, and 2022, respectively. As of September 2024, the company employs 914 people in various departments. Competitive Strengths: Established quality credentials with a strong focus on quality control management. Successful integration of growth opportunities through acquisitions. Global and diverse management team with deep scientific expertise.